Improving the Management of Drug Resistant Tuberculosis in the UK
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The 'rising tide' of antimicrobial resistance is a source of concern across most infectious
diseases. In the UK, for example, 6.8% of the ~8,500 tuberculosis patients seen in 2012 were
resistant to the cheap and effective first-line drug isoniazid. It is of great importance to
prevent the loss of current anti-tuberculosis drugs and preventing the spread of resistance
by treating such patients as well as possible.
Currently, guidance on the best treatments for isoniazid resistant tuberculosis is
inconsistent globally. Data from randomised controlled trials, the peak quality of evidence,
is sparse. It is thus important that studies using pre-existing observational data are
undertaken.
The investigators aim to use data and samples collected from Public Health England and
National Health Service hospitals to determine a) the best treatments for patients with
isoniazid resistant tuberculosis disease (cohort study) and b) how different causes of drug
resistance in the infecting bacteria influence a) (nested case-control study). Eligible
participants will have had isoniazid resistant tuberculosis (without associated rifampicin
resistance) in England between 2009 and 2013 and will have been notified to Public Health
England. The study will be conducted at University College London, National Health Service
hospitals and Public Health England and will last until December 2017. Patient hospital
records and disease surveillance records will be accessed and cultured bacteria from
previously stored samples sequenced.
Details
Lead Sponsor:
University College, London
Collaborator:
National Institute for Health Research, United Kingdom